Anesthetic Management of Pheochromocytomas in a Specialized Endocrinology Center

Authors

  • S.M. Cherenko Ukrainian Scientific and Practical Centre for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Healthcare of Ukraine, Kyiv, Ukraine
  • S.O. Dubrov National Medical University named after O.O. Bohomolets, Kyiv, Ukraine
  • M.V. Kunatovskyi Ukrainian Scientific and Practical Centre for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Healthcare of Ukraine, Kyiv, Ukraine
  • O.A. Tovkai Ukrainian Scientific and Practical Centre for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Healthcare of Ukraine, Kyiv, Ukraine
  • S.O. Tarasenko Ukrainian Scientific and Practical Centre for Endocrine Surgery, Transplantation of Endocrine Organs and Tissues of the Ministry of Healthcare of Ukraine, Kyiv, Ukraine

DOI:

https://doi.org/10.22141/2224-0721.2.74.2016.70952

Keywords:

pheochromocytoma, anesthesia, staged perioperative hemodynamic management, urapidil, refortan.

Abstract

bjective: the introduction of modern anesthetic management of patients with pheochromocytoma in a specialized endocrinology center using the algorithm of staged perioperative hemodynamic monitoring.
Materials and methods. The implementation of anesthetic management has been carried out in 33 women with adrenal pheochromocytomas during their surgical removal by means of video-assisted laparoscopic adrenalectomy. In all patients, we have used an algorithm of staged perioperative hemodynamic management (SPOHM): preoperative tablet hypotensive therapy before admission to the hospital; preoperative infusion controlled hypotensive therapy by urapidil and correction of hypovolemia by balanced crystalloid solutions and a 10% solution of hydroxyethyl starch (HES) (200/0.5) on the 2nd stage; intraoperative infusion controlled antihypertensive therapy by urapidil on the 3rd stage under the control of invasive and non-invasive hemodynamic monitoring and prevention of adrenal insufficiency and hypovolemia correction on the 4th stage.
Results and discussion. All patients had significantly (p < 0.001) increased levels of daily urine metanephrines up to 1,831.6 ± 337.9 mg/24 h (control 169.3 ± 12.7 mg/24 h). According to the developed SPOHM algorithm, doxazosin at a dose of 10.0 ± 1.0 mg or urapidil at a dose of 144.0 ± 11.2 mg were used twice daily in the first stage. On the second stage, hemodilution by 10 % solution of HES (200/0.5) and controlled infusion antihypertensive therapy by urapidil with an average rate of 9.7 ± 1.9 mg/hr were performed. In the third stage, intraoperatively the rate of urapidil infusion was 1.25 ± 0.08 mg/min (additionally, during surgical removal of adrenal gland with pheochromocytoma, urapidil bolus 25–50 mg i/v was administered even when the slightest increase of blood pressure was detected). On the fourth stage, the prevention of adrenal insufficiency and hypovolemia was conducted.
Conclusions. The introduction of anesthetic management of patients with pheochromocytoma in a specialized endocrinology center has ensured the high efficiency and safety of laparoscopic adrenalectomy under general anesthesia and the absence of lethal cases. SPOHM in preparation for the surgery and during surgical intervention is an effective, easily manageable and safe method for stabilization of hemodynamic markers in pheochromocytoma patients during adrenalectomy.

Downloads

Download data is not yet available.

References

Chen H., Sippel R.S., O’Dorisio M.S., Vinik A.I., Lloyd R.V., Pacak K. North American Neuroendocrine Tumor Society (NANETS). The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Pheochromocytoma, Paraganglioma, and Medullary Thyroid Cancer // Pancreas. — 2010. — ​Vol. 39. — ​Р. 775-783.

Pacak K., Eisenhofer G., Ahlman H., Bornstein S.R., Gimenez-Roqueplo A.P., Grossman A.B., Kimura N., Mannelli M., McNicol A.M. and Tischler A.S. International Symposium on Pheochromocytoma. Pheochromocytoma: Recommendations for Clinical Practice from the First International Symposium. October 2005 // Nature Clinical Practice Endocrinology & Metabolism. 2007. — ​Vol. 3. — ​Р. 92-102.

Young W.F. Williams Textbook of Endocrinology. — ​Philadelphia: Saunders Elsevier, 2008.

Lenders J.W., Eisenhofer G., Mannelli M., Pacak K. Phaeochromocytoma // Lancet. — 2005. — ​Vol. 20–26, № 366. — ​Р. 665-675.

Bajwa S.S., Bajwa S.K. Implications and Considerations during Pheochromocytoma Resection: A Challenge to the Anesthesiologist // Indian Journal of Endocrinology & Metabolism. — 2011. — ​Vol. 15, № S4. — ​Р. S337-S344.

Eisenhofer G., Rivers G., Rosas A.L., Quezado Z., Manger W.M. and Pacak K. Adverse Drug Reactions in Patients with Phaeochromocytoma: Incidence, Prevention and Management // Drug Safety. — 2007. — ​Vol. 30. — ​Р. 1031-1062.

Kinney M.A., Narr B.J., Warner M.A. Perioperative Management of Pheochromocytoma // Journal of Cardiothoracic and Vascular Anesthesia. — 2002. — ​Vol. 16. — ​Р. 359-369.

Habbe N., Ruger F., Bojunga J., Bechstein W.O., Holzer K. Urapidil in the preoperative treatment of pheochromocytomas: a safe and cost-effective method // World J. Surg. — 2013 May. — 37(5). — 1141-6.

Steib A., Collin F., Stojeba N., Coron T., Weber J.C., Beller J.P. Use of urapidil during surgery for pheochromocytoma // Ann. Fr. Anesth. Reanim. — 1996. — 15(2). — 142-8.

Pacak K. Preoperative Management of the Pheochromocytoma Patient // Indian Journal of Endocrinology & Metabolism. — 2007. — ​Vol. 92. — ​Р. 4069-4079.

Lentschener C., Gaujoux S., Tesniere A. and Dousset B. Point of Controversy: Perioperative Care of Patients Undergoing Pheochromocytoma Removal-Time for a Reappraisal? // European Journal of Endocrinology. — 2011. — ​Vol. 165. — ​Р. 365-373.

Wall R.T. Stoelting’s Anesthesia and Co-Existing Disease. — ​Philadelphia: Saunders Elsevier, 2008.

Jugovac І., Antapli M., Markan S. Anesthesia and Pheochromocytoma // International Anesthesiology Clinics. — 2011. — ​Vol. 49. — ​Р. 57-61.

Westfall T.C., Westfall D.P. The Pharmacologycal Basis of Therapeutics. — ​New York: McGraw Hill, 2011.

Bruynzeel H., Feelders R.A., Groenland T.H., vanden Meiracker A.H., van Eijck C.H., Lange J.F., de Herder W.W., Kazemier G. Risk Factors for Hemodynamic Instability during Surgery for Pheochromocytoma // Journal of Clinical Endocrinology & Metabolism. — 2010. — ​Vol. 95. — ​Р. 678-685.

Nizamoğlu A., Salihoğlu Z., Bolayrl M. Effects of Epidural-and-General Anesthesia Combined versus General Anesthesia during Laparoscopic Adrenalectomy // Surgical Laparoscopy Endoscopy & Percutaneous Techniques. — 2011. — ​Vol. 21. — ​Р. 372-379.

Isosu T., Obara S., Ohashi S., Hosono A., Nakano Y., Imaizumi T., Mogami M., Iida H., Murakawa M. Examination of the Usefulness of Non-Invasive Stroke Volume Variation Monitoring for Adjusting Fluid Supplementation during Laparoscopic Adrenalectomy in Patients with Pheochromocytoma // Fukushima Journal of Medical Science. — 2012. — ​Vol. 58. — ​Р. 78-81.

Domia R., Sulaa H. Pheochromocytoma, the Challenge to Anesthesiologists // Journal of Endocrinology & Metabolism. — 2011. — ​Vol. 1. — ​Р. 97-100.

Kinney M.A., Warner M.E., van Heerden J.A., Horlocker T.T., Young W.F. Jr, Schroeder D.R., Maxson P.M., Warner M.A. Perianesthetic Risks and Outcomes of Pheochromocytoma and Paraganglioma Resection // Anesthesia & Analgesia. — 2000. — ​Vol. 91. — ​Р. 1118-1123.

James M.F., Cronjé L. Pheochromocytoma Crisis: The Use of Magnesium Sulfate // Anesthesia & Analgesia. — 2004. — ​Vol. 99. — ​Р. 680-686.

Herroeder S., Schönherr M.E., De Hert S.G., Hollmann M.W. Magnesium — ​Essentials for Anesthesiologists // Anesthesiology. — 2011. — ​Vol. 114. — ​Р. 971-993.

Lord M.S., Augoustides J.G. Perioperative Management of Pheochromocytoma: Focus on Magnesium, Clevidipine, and Vasopressin // Journal of Cardiothoracic and Vascular Anesthesia. — 2012. — ​Vol. 26. — ​Р. 526-531.

Van der Horst-Schrivers A.N., Kerstens M.N., Wolffenbuttel B.H. Preoperative Pharmacological Management of Phaeochromocytoma // Netherlands Journal of Medicine. — 2006. — ​Vol. 64. — ​Р. 290-295.

Guillemot J., Compagnon P., Cartier D., Thouennon E., Bastard C., Lihrmann I., Pichon P., Thuillez C., Plouin P.F., Bertherat J., Anouar Y., Kuhn J.M., Yon L., Lefebvre H. Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5-HT4) receptors // Endocr. Relat Cancer. — 2009 Mar. — 16(1). — 281-90. doi: 10.1677/ERC‑08-0190. Epub 2008 Oct 23.

Daniel D. Kim, Christiano Matsui, Judymara L. Gozzani, Ligia A.S.T. Mathias. Pheochromocytoma Anesthetic Management // Open Journal of Anesthesiology. — 2013. — 3. — 152-155.

Інструкція з медичного застосування препарату Рефортан плюс 10 %, Р.П. № UA/6680/01/01 від от 28.09.2012. Наказ МОЗ № 755 від 28.09.2012.

Дубров С.О., Глумчер Ф.С., Гавриленко О.О., Тарасенко С.О., Сем’янків А.М. Профілактика венозних тромбоемболічних ускладнень у пацієнтів у торакальній хірургії / // Досягнення біології та медицини. — 2012. — № 1(19). — ​С. 43-46.

Published

2021-09-03

How to Cite

Cherenko, S., Dubrov, S., Kunatovskyi, M., Tovkai, O., & Tarasenko, S. (2021). Anesthetic Management of Pheochromocytomas in a Specialized Endocrinology Center. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), (2.74), 115–123. https://doi.org/10.22141/2224-0721.2.74.2016.70952

Issue

Section

Endocrine Surgery

Most read articles by the same author(s)

1 2 > >>